Santen CIO Minori Hara explains how IT is enabling the ophthalmological company to deliver a holistic sense of well-being around eye health.
Posts Tagged: Insights on Pharmaceuticals & Medical Products
Key stakeholders will need to continue to monitor and adapt to new data and new variants emerging across the globe to respond effectively.
Increasingly, small biopharmaceutical companies are launching their new drugs themselves rather than relying on large pharma companies to do it for them. How can they get it right the first time?
Companies that invest inorganically during a downturn generally emerge stronger than their competitors. Japanese medtech companies have the cash, the incentive, and the opportunity to do just that.
An emerging model for biotech companies could disrupt the R&D landscape and open up new ways to invest, motivate teams, and shape the innovation pipeline.
Pharmaceutical and medtech companies can dramatically improve quality assurance processes by applying a ‘smart quality’ lens and cutting-edge technologies.
Pharma and medtech companies that adopt a proactive approach to managing the quality function can generate value far beyond improved regulatory compliance.
The speed at which scientific breakthroughs in cell and gene therapy translate into advances in European healthcare could depend on how quickly stakeholders address some uniquely European challenges.
Building a successful digital health business involves several strategic steps, as illustrated through the lens of six digital health start-ups.
Biopharma in 2020 has shown what it can achieve when it works at its best. How can the industry build on this renewed sense of purpose in the years ahead?